



● EGFR inhibitors

Discovery	Cat.No.	Product Name	Information				Clinical Trial
1997	S1023	Erlotinib HCl (OSI-744)	Targets	EGFR			Phase 2
			IC ₅₀ (nM)	2			
2005	S1025	Gefitinib (ZD1839)	Targets	Tyr1173 (NR6wtEGFR cells)	Tyr992 (NR6wtEGFR cells)	Tyr1173 (NR6W cells)	Phase 3
			IC ₅₀ (nM)	37	37	57	
2008	S1011	Afatinib (BIBW2992)	Targets	EGFR ^{wt}	EGFR ^{L858R}	EGFR ^{L858R/T790M}	Phase 3
			IC ₅₀ (nM)	0.5	0.4	10	
2001	S2111	Lapatinib	Targets	EGFR	ErbB2		Phase 3
			IC ₅₀ (nM)	10.8	9.2		
2009	S1173	WZ4002	Targets	EGFR ^{L858R}	EGFR ^{L858R/T790M}		
			IC ₅₀ (nM)	2	8		
2001	S1028	Lapatinib	Targets	EGFR	ErbB2		Phase 2
			IC ₅₀ (nM)	10.8	9.2		
2004	S2150	Neratinib (HKI-272)	Targets	EGFR	HER2		Phase 2
			IC ₅₀ (nM)	92	59		
2007	S2727	Dacomitinib	Targets	EGFR	ErbB2	ErbB4	Phase 2
			IC ₅₀ (nM)	6	45.7	73.7	
1991	S1143	AG-490	Targets	EGFR	ErbB2	JAK2	
			IC ₅₀ (μM)	0.1	13.5	~10	
1989	S8009	AG-18	Targets	EGFR			
			IC ₅₀ (μM)	35			
1998	S7039	PD168393	Targets	EGFR			
			IC ₅₀ (nM)	0.7			